Collection and distribution of biospecimens for research purposes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to establish a network of hospitals, laboratories, and academic institutions to provide researchers with annotated biospecimens for various medical research applications. Participants, including both healthy individuals and those with medical conditions, will be approached during clinical care or through outreach programs to provide biospecimens. The study focuses on understanding the impact of specimen collection methods on research outcomes and facilitating biomarker discovery, diagnostic test development, and therapeutic advancements. Minimal risk screening activities will be conducted to determine eligibility for participation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individual is developmentally aged 7 years old and above for RUO collections (only)
* Individual meets requirements of a current request for research materials from iSpecimen
* If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and/or the review of an updated medical history as provided by the participant
* Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf.
* Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf

Exclusion Criteria:

* Subjects that do not meet the inclusion criteria outlined above.

Where it's running

• iSpecimen
  Huntsville, Alabama, United States Recruiting
• iSpecimen
  Lexington, Massachusetts, United States Active not recruiting

Study contacts

• Study coordinator: Emily L Hubbard
• Email: ehubbard@ispecimen.com
• Phone: 2567970003

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Music-4-MS: A 12-week music-based program to support thinking skills in people with MS

  A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.

  Recruiting University of Texas at Austin · Austin, Texas · NCT07759115

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• AMX0035 in adults with Type 1 Diabetes

  This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.

  Recruiting Phase 2 University of Washington · Seattle, Washington and 1 other locations · NCT07699380

• Tegoprazan to prevent GI complications in ischemic stroke patients on antiplatelet therapy

  This trial tests whether tegoprazan can lower gastrointestinal complications in adults with ischemic stroke or TIA who are starting antiplatelet therapy.

  Recruiting at 24 sites Phase 3 Hanyang University · Busan, Busan and 23 other locations · NCT07687706

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.